Drug Trial Radar · NCT00261846
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Last checked: Nov 20, 2026Latest source record: Jul 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
571
Actual
Start
Jan 18, 2006
Primary completion
Sep 25, 2009
Study completion Aug 6, 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a dose-escalation study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to establish the maximum tolerated dose (MTD) in this subject population. Part 2 has begun after the completion of Part 1 and after a dose has been established for the compound in chronic phase subjects. Part 2 is a study of the the efficacy of 500mg daily oral SKI-606 (bosutinib) in patients with all phases of Ph+ CML and Ph+ Acute Lymphocytic Leukemia (ALL). The protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will attain (1) Major Cytogenetic Response (MCyR) in chronic phase CML patients and (2) Overall Hematological Response (OHR) in advanced leukemia patients. Each phase of the disease will be evaluated as a separate cohort.
Conditions
- Chronic Myeloid Leukemia
Interventions
BosutinibDrug
Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component. Part 2, 500 mg oral, continuous, daily dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Part 1 Baseline up to Day 28
- Maximum Tolerated Dose (MTD)Time frame: Part 1 Baseline up to Day 28
- Maximum Observed Plasma Concentration (Cmax) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Plasma Decay Half-Life (t1/2) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC(0-48)] - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Area Under the Concentration-Time Curve (AUC) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Apparent Oral Clearance (CL/F) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Apparent Volume of Distribution (Vz/F) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
- Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
- Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
- Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
- Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
- Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
- Accumulation Ratio (R)Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 and Day 15
- Percentage of Participants With MCyR at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2Time frame: Week 24
Locations
111 sites in 27 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
HealthONE Presbyterian
Denver, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
Georgetown University Hospital
Washington D.C., District of Columbia
Emory Clinic
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Winship Cancer Institute
Atlanta, Georgia
Oncology Specialists, S.C.
Niles, Illinois
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana
LSU Health Sciences Center
Shreveport, Louisiana
University Of Maryland Medical Center
Baltimore, Maryland
University Of Maryland
Baltimore, Maryland
Roswell Park Cancer Institute
Buffalo, New York
Hudson Valley Hematology and Oncology Associates
Hawthorne, New York
Westchester Oncology Hematology Group, P.C.
Hawthorne, New York
Westchester Oncology Hematology, Group, P.C.
Hawthorne, New York
New York Presbyterian Hospital
New York, New York
New York Presbyterian Hospital
New York, New York
University of Rochester Cancer Center Pharmacy
Rochester, New York
University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center
Rochester, New York
University of Rochester Medical Center
Rochester, New York
University of Rochester-James P. Wilmot Cancer Center
Rochester, New York
University of Rochester
Rochester, New York
Westchester Medical Center
Valhalla, New York
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
The University of Texas
Houston, Texas
Virginia Commonwealth University
Richmond, Virginia
Hospital Britanico
Buenos Aires, Argentina
Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas
Buenos Aires, Argentina
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Argentina
Clinica del Sol
Buenos Aires, Argentina
Centro Medico S.A.
Corrientes, Argentina
Hospital Jose Ramon Vidal
Corrientes, Argentina
Hospital universitario austral
Pcia de Buenos Aires, Argentina, Argentina
Hospital Italiano de la Plata
La Plata, Buenos Aires, Argentina
Institute of Medical and Veterinary Science
Adelaide, Australia
Department of Clinical Haematology and Bone Marrow Transplantation
Melbourne, Australia
Royal Brisbane and Women's Hospital
Queensland, Australia
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.